Brought to you by 
Janssen partners with GlycoVaxyn to create bacterial vaccine
17 Jan 2013
Executive Summary
Johnson & Johnson’s Janssen Pharmaceuticals Inc. has signed a three-year R&D agreement with GlycoVaxyn AG (vaccines) under which the companies will develop a multi-valent bacterial vaccine that employs GlycoVaxyn’s bioconjugation technology.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Synthesis Technologies, Production Processes
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Janssen partners with GlycoVaxyn to create bacterial vaccine
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice